ClinicalTrials.gg
CompletedNCT00461617Updated Oct 21, 2008

Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients

A Phase 3 interventional study of Mitiglinide in Diabetes, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-10-21.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
291
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.

02

Conditions studied

  • Diabetes

Keywords

  • diabetes
  • rapid and short acting insulin secretagogue
  • α-glucosidase inhibitor
  • HbA1C
  • insulin
03

In context

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

This study's enrollment of 291 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes patients with inadequate control of blood glucose with diet and/or exercise therapy

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes patients
  • Patients who require treatment with insulin
  • Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)
  • Patients with severe ketosis, diabetic coma or precoma
  • Patients complicated with severe hepatic diseases
  • Patients complicated with severe renal diseases
  • Patients complicated with severe hypertension
  • Patients complicated with severe cardiac disease
  • Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
291 participants (actual)

Study arms

  • Active comparator
    2

    Nateglinide 120 mg TID

    Drug: Mitiglinide

Interventions

  • 10mg tablet, 10mg TID

    Also known as: Glufast

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1C (HbA1C)

    Time frame: -2, 0, 4, 8, 10, 12, 16, 20 week

Secondary outcomes

  1. Fasting plasma glucose level (FPG)

    Time frame: 0, 4, 8, 12, 16, 20 week

  2. Two-hour postprandial glucose level (PPG2)

    Time frame: 0, 12, 20 week

  3. One-hour postprandial glucose level (PPG1)

    Time frame: 0, 12, 20 week

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2007
First posted
Apr 18, 2007
Start
Aug 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Oct 21, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00461617
First posted
Apr 18, 2007
Start date
Aug 2006
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Oct 21, 2008

Study contacts

Xin Gao, Professor
principal investigator · Endocrinology Dept. of Fudan University Zhongshan Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitiglinide

Start the discussion